Design and Rationale of the Metastatic Renal Cell Carcinoma (MaRCC) Registry: A Prospective Academic and Community-Based Study of Patients With Metastatic Renal Cell Cancer.
Publication
, Journal Article
Bhavsar, NA; Harrison, MR; Hirsch, BR; Creel, P; Wolf, SP; Samsa, GP; Abernethy, AP; Simantov, R; Borham, A; George, DJ
Published in: Cancer Invest
May 28, 2017
The Metastatic Renal Cell Cancer Registry, a large, nationally representative, prospective registry of patients with metastatic renal cell carcinoma (mRCC), aims to understand real-world treatment patterns and outcomes of patients with mRCC in routine clinical practice across the United States. This observational study is designed to enroll 500 patients with previously untreated mRCC from approximately 60 academic and community treatment sites; as of December 7, 2016, 500 patients have enrolled at 54 sites. Key endpoints include real-world data on reasons for treatment initiation and discontinuation; treatment regimens; disease progression; patient-reported outcomes; and healthcare resource utilization in this patient population.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Cancer Invest
DOI
EISSN
1532-4192
Publication Date
May 28, 2017
Volume
35
Issue
5
Start / End Page
333 / 344
Location
England
Related Subject Headings
- United States
- Treatment Outcome
- Time Factors
- Research Design
- Registries
- Quality of Life
- Prospective Studies
- Practice Patterns, Physicians'
- Patient Reported Outcome Measures
- Oncology & Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Bhavsar, N. A., Harrison, M. R., Hirsch, B. R., Creel, P., Wolf, S. P., Samsa, G. P., … George, D. J. (2017). Design and Rationale of the Metastatic Renal Cell Carcinoma (MaRCC) Registry: A Prospective Academic and Community-Based Study of Patients With Metastatic Renal Cell Cancer. Cancer Invest, 35(5), 333–344. https://doi.org/10.1080/07357907.2017.1289215
Bhavsar, Nrupen A., Michael R. Harrison, Bradford R. Hirsch, Patricia Creel, Steve P. Wolf, Greg P. Samsa, Amy P. Abernethy, Ronit Simantov, Azah Borham, and Daniel J. George. “Design and Rationale of the Metastatic Renal Cell Carcinoma (MaRCC) Registry: A Prospective Academic and Community-Based Study of Patients With Metastatic Renal Cell Cancer.” Cancer Invest 35, no. 5 (May 28, 2017): 333–44. https://doi.org/10.1080/07357907.2017.1289215.
Bhavsar NA, Harrison MR, Hirsch BR, Creel P, Wolf SP, Samsa GP, et al. Design and Rationale of the Metastatic Renal Cell Carcinoma (MaRCC) Registry: A Prospective Academic and Community-Based Study of Patients With Metastatic Renal Cell Cancer. Cancer Invest. 2017 May 28;35(5):333–44.
Bhavsar, Nrupen A., et al. “Design and Rationale of the Metastatic Renal Cell Carcinoma (MaRCC) Registry: A Prospective Academic and Community-Based Study of Patients With Metastatic Renal Cell Cancer.” Cancer Invest, vol. 35, no. 5, May 2017, pp. 333–44. Pubmed, doi:10.1080/07357907.2017.1289215.
Bhavsar NA, Harrison MR, Hirsch BR, Creel P, Wolf SP, Samsa GP, Abernethy AP, Simantov R, Borham A, George DJ. Design and Rationale of the Metastatic Renal Cell Carcinoma (MaRCC) Registry: A Prospective Academic and Community-Based Study of Patients With Metastatic Renal Cell Cancer. Cancer Invest. 2017 May 28;35(5):333–344.
Published In
Cancer Invest
DOI
EISSN
1532-4192
Publication Date
May 28, 2017
Volume
35
Issue
5
Start / End Page
333 / 344
Location
England
Related Subject Headings
- United States
- Treatment Outcome
- Time Factors
- Research Design
- Registries
- Quality of Life
- Prospective Studies
- Practice Patterns, Physicians'
- Patient Reported Outcome Measures
- Oncology & Carcinogenesis